virus
ebolaviru
genu
caus
sporad
epidem
sever
system
febril
diseas
fuel
humantohuman
transmiss
despit
notorieti
ebolavirus
particularli
ebola
viru
ebov
promin
viral
hemorrhag
fever
agent
intern
concern
regard
ebola
viru
diseas
evd
outbreak
littl
known
pathophysiolog
evd
human
particular
human
immun
correl
surviv
immun
memori
lack
basic
knowledg
physiolog
characterist
evd
probabl
attribut
dearth
clinic
laboratori
data
gather
past
outbreak
unpreced
magnitud
evd
epidem
occur
west
africa
allow
first
time
evalu
clinic
epidemiolog
immunolog
paramet
signific
number
patient
use
stateoftheart
laboratori
equip
review
summar
data
literatur
regard
human
pathophysiolog
immunolog
respons
filovir
infect
ebola
viru
ebov
prototyp
member
ebolaviru
genu
filovirida
famili
negativesens
singlestrand
rna
virus
discov
first
document
outbreak
ebola
viru
diseas
evd
town
yambuku
northern
zair
today
democrat
republ
congo
ebov
sinc
caus
sporad
human
diseas
outbreak
vari
magnitud
equatori
african
countri
sanchez
et
al
march
ebov
variant
later
name
ebov
makona
first
detect
guinea
variant
respons
epidem
affect
ten
thousand
peopl
sever
west
african
countri
collaps
healthcar
system
three
ebov
makona
rampag
rural
urban
area
underscor
previous
poorli
character
featur
evd
like
sexual
transmiss
viru
persist
recoveri
row
et
al
chughtai
et
al
deen
et
al
fischer
et
al
rodriguez
et
al
varkey
et
al
uyeki
et
al
scientif
clinic
knowledg
human
evd
appear
west
africa
limit
scarciti
human
case
occurr
rural
area
equatori
africa
limit
research
confin
filoviru
research
biosafeti
level
contain
laboratori
addit
basic
studi
evd
pathophysiolog
hamper
lack
suscept
small
anim
model
compet
immun
exampl
laboratori
mice
commonli
use
diseas
model
complet
resist
nonadapt
ebov
evd
describ
acut
hemorrhag
fever
thu
earn
former
name
ebola
hemorrhag
fever
ehf
case
fatal
rate
report
diseas
character
lymphopenia
dissemin
intravascular
coagul
dic
immunosuppress
system
inflammatori
respons
resembl
septic
shock
feldmann
geisbert
mani
observ
strengthen
find
west
african
evd
outbreak
previou
hypothes
revis
perhap
one
surpris
find
low
overal
number
human
case
present
bleed
schieffelin
et
al
well
lack
correl
bleed
diseas
sever
schieffelin
et
al
mcelroy
et
al
b
find
trigger
chang
diseas
nomenclatur
ebola
hemorrhag
fever
ebola
viru
diseas
moreov
find
evd
correl
robust
immun
activ
rather
immunosuppress
mcelroy
et
al
abil
viru
persist
sever
bodi
fluid
long
recoveri
varkey
et
al
uyeki
et
al
sow
et
al
green
et
al
deen
et
al
chang
current
view
evd
prompt
new
direct
research
new
public
health
polici
aim
integr
novel
find
within
current
human
evd
model
discuss
futur
research
direct
sever
ebolavirus
caus
evd
differ
may
exist
diseas
caus
individu
virus
review
focu
evd
diseas
caus
known
virus
ebolaviru
genu
ebolavirus
pathogen
human
reader
note
avail
data
come
infect
caus
ebov
rather
pathogen
virus
genu
sudan
viru
sudv
bundibugyo
viru
bdbv
forest
viru
tafv
relat
marburgvirus
marburg
viru
marv
ravn
viru
ravv
mention
appropri
data
avail
unfortun
inform
marburg
viru
diseas
mvd
caus
still
lack
epidemiolog
data
collect
last
year
indic
human
infect
ebov
occur
mainli
close
contact
infect
bodi
fluid
probabl
occur
spillov
event
eg
contact
infect
blood
butcher
bushmeat
humantohuman
transmiss
evid
direct
contact
bat
caus
ebov
spillov
human
mari
saez
et
al
leroy
et
al
infect
marv
ravv
via
direct
indirect
contact
egyptian
rousett
fruit
bat
speci
rousettu
aegyptiacu
amman
et
al
schuh
et
al
document
human
visit
cave
mine
bat
roost
directli
associ
develop
mvd
bausch
et
al
center
diseas
prevent
adjemian
et
al
strongli
indic
mucos
skin
contact
bat
drop
suffici
initi
marv
infect
human
except
first
evd
outbreak
zair
link
substanti
percutan
needl
transmiss
ebola
haemorrhag
fever
zair
data
sinc
earli
suggest
expos
skin
mucosa
ebov
conduct
activ
like
bodi
wash
tradit
funer
care
sick
rel
household
suffici
humantohuman
transmiss
ebov
dowel
et
al
francesconi
et
al
earli
data
collect
laboratori
exposur
sudv
even
suggest
skin
abras
may
necessari
allow
ebolaviru
entri
skin
emond
et
al
find
rais
question
regard
ebolaviru
infect
take
place
skin
mucosa
cell
involv
primari
amplif
viru
antigenpres
cell
put
initi
target
ebov
infect
previou
research
anim
model
diseas
indic
dendrit
cell
dc
macrophag
earli
prefer
target
ebov
support
viru
replic
geisbert
et
al
dc
macrophag
also
product
infect
ebov
vitro
gupta
et
al
gupta
et
al
mahanti
et
al
bosio
et
al
ebov
prevent
activ
vitroderiv
dc
mainli
action
yen
et
al
jin
et
al
ilinykh
et
al
complic
thing
great
deal
research
last
decad
devot
defin
ontogeni
specif
function
dc
subset
mice
human
emerg
pictur
sever
cell
subset
exist
overlap
nonoverlap
function
subset
roughli
classifi
classic
plasmacytoid
inflammatori
dc
human
see
haniffa
et
al
excel
review
whether
ebov
equal
infect
differ
dc
subset
known
exist
evid
suggest
leung
et
al
exampl
number
cellular
receptor
involv
attach
ebov
virion
target
cell
receptor
includ
sever
ctype
lectin
present
surfac
dc
dendrit
cellspecif
nonintegrin
dcsign
simmon
et
al
liverlymph
node
sign
lsign
dc
epidermi
mucos
epithelium
express
molecul
langerhan
cell
skin
dc
mucos
epithelium
express
ctype
lectin
langerin
merad
et
al
fact
studi
monkey
pig
indic
dcsign
cell
scarc
dermi
lamina
propria
submucosa
steadi
state
schwartz
et
al
huang
et
al
suggest
cell
type
may
target
earli
ebov
replic
initi
ebov
infect
may
depend
attach
target
cell
via
highli
express
mucos
epithelia
rhein
et
al
kondratowicz
et
al
initi
viru
amplif
could
lead
inflamm
infiltr
high
number
myeloid
cell
express
dcsign
describ
ebov
attach
factor
like
trigger
receptor
express
myeloid
cell
express
neutrophil
mohamadzadeh
et
al
human
macrophag
ctype
lectin
specif
galactosenacetylgalactosamin
hmgl
express
macrophag
takada
et
al
elucid
initi
step
ebov
establish
product
infect
host
organ
highli
need
understand
mechan
viru
dissemin
initi
site
entri
bodi
perhap
design
medic
countermeasur
aim
prevent
viru
spread
mention
dc
macrophag
earli
target
ebov
infect
due
migratori
potenti
dc
immun
cell
may
particip
dissemin
ebov
initi
point
entri
drain
lymph
node
geisbert
et
al
strategi
commonli
use
virus
includ
sar
coronaviru
toscana
viru
cusi
et
al
measl
viru
mesman
et
al
dissemin
host
howev
perhap
due
lack
suitabl
vivo
model
kinet
studi
ebov
involv
dc
ebov
dissemin
experiment
address
case
specif
subset
cell
respons
ebov
dissemin
remain
identifi
plausibl
tissueresid
dc
inflammatori
dc
deriv
infiltr
monocyt
import
ebov
dissemin
myeloid
dc
popul
migratori
transport
varieti
antigen
inflam
tissu
drain
lymph
node
leon
et
al
ersland
et
al
convers
macrophag
neutrophil
less
like
particip
ebov
dissemin
due
low
mobil
nonproduct
infect
respect
mohamadzadeh
et
al
recent
studi
demonstr
human
evd
associ
loss
peripher
blood
monocyt
particular
nonclass
monocyt
propos
main
antivir
monocyt
subset
cro
et
al
even
though
studi
demonstr
direct
infect
ebov
rais
possibl
cell
subset
could
involv
viru
dissemin
fact
monocyt
also
call
patrol
monocyt
due
abil
attach
endotheli
cell
manner
extravas
inflam
tissu
differenti
inflammatori
dc
macrophag
cro
et
al
auffray
et
al
hypothesi
also
substanti
previou
studi
demonstr
ebov
particl
attach
monocyt
enter
cell
monocyt
differenti
program
start
differenti
dc
macrophag
inflam
tissu
martinez
et
al
identif
dc
subset
specif
involv
filoviru
dissemin
highli
relev
topic
studi
function
dc
enhanc
inhibit
ex
vivo
vivo
antigen
deliveri
use
molecul
antibodi
therefor
dc
put
immunotherapeut
target
postexposur
evd
treatment
klechevski
banchereau
exampl
ligand
dc
costimulatori
molecul
commonli
use
enhanc
dcmediat
antigen
present
kornbluth
bot
previou
studi
demonstr
correl
circul
level
surviv
sudv
infect
mcelroy
et
al
b
addit
poor
activ
profil
circul
antigenpres
cell
correl
sever
evd
find
provid
rational
use
dc
enhanc
immunotherapi
candid
filoviru
diseas
anoth
key
driver
ebov
dissemin
may
cytokin
microenviron
sinc
innat
immun
signal
molecul
play
import
role
recruit
myeloid
cell
put
ebov
target
site
inflamm
consider
bodi
research
exist
cytokin
chemokin
respons
evd
despit
conflict
gener
data
correl
fatal
outcom
evd
high
concentr
proinflammatori
cytokin
eg
proinflammatori
chemokin
eg
antiinflammatori
cytokin
ilra
overal
suggest
gener
dysregul
express
key
immun
signal
molecul
hutchinson
rollin
gupta
et
al
wauquier
et
al
baiz
et
al
villing
et
al
inabl
control
viral
replic
like
lead
continu
innat
immun
stimul
data
asymptomat
human
case
shown
even
greater
magnitud
cytokin
chemokin
upregul
follow
rapid
downregul
respons
associ
control
viral
replic
leroy
et
al
leroy
et
al
suggest
cytokinechemokin
dysregul
consequ
uncontrol
viral
replic
rather
primari
mediat
pathogenesi
type
interferon
ifni
key
antivir
cytokin
perhap
one
conflict
aspect
compar
ebov
experiment
clinic
human
data
role
ifni
ebov
immun
pathogenesi
importantli
ifni
induc
antivir
state
infect
bystand
cell
earli
viru
infect
also
key
modul
transit
innat
adapt
immun
enhanc
natur
killer
cell
function
antigen
present
dc
expans
effector
cell
ifni
bridg
natur
acquir
antivir
immun
see
mcnab
et
al
review
elucid
function
human
evd
highli
relev
understand
diseas
pathogenesi
ifn
critic
protect
laboratori
mice
ebov
brannan
et
al
bray
et
al
data
somewhat
conflict
nonhuman
primat
nhp
human
smith
et
al
villing
et
al
yen
et
al
higher
level
ifnalpha
associ
fatal
evd
case
villing
et
al
higher
ifnbeta
associ
less
sever
evd
ifnbeta
administr
prolong
surviv
nonhuman
primat
smith
et
al
howev
ifn
respons
highli
dynam
draw
conclus
regard
human
pathogenesi
difficult
exampl
evd
survivor
may
mount
earli
robust
ifn
respons
keep
viral
replic
bay
patient
succumb
evd
may
display
higher
ifn
level
later
due
increas
viral
replic
inflamm
interestingli
recent
studi
shown
patient
surviv
patient
succumb
evd
show
robust
cell
activ
mcelroy
et
al
ruibal
et
al
sinc
dc
antigenpres
cell
capabl
prime
cell
banchereau
steinman
result
suggest
least
two
possibl
one
hand
infect
dc
may
retain
capac
initi
cellspecif
respons
shown
viral
infect
wahid
et
al
rivera
mcguir
kvale
et
al
hand
dc
subset
may
spare
infect
thu
abl
prime
ebovspecif
cell
gener
ebovspecif
adapt
immun
topic
next
two
section
innat
immun
respons
may
play
chief
role
control
earli
ebov
replic
human
current
model
identifi
charact
though
necessarili
magnitud
adapt
immun
main
factor
drive
viral
clearanc
recoveri
humor
cellular
immun
seem
requir
ebov
clearanc
human
hypothesi
strengthen
find
evd
patient
mount
robust
adapt
immun
respons
mcelroy
et
al
ruibal
et
al
high
number
circul
plasmablast
ebovspecif
cell
difficult
task
assess
whether
adapt
immun
respons
mark
substanti
differ
fatal
surviv
patient
initi
studi
support
idea
earli
develop
igm
isotyp
switch
igg
correl
posit
outcom
inde
high
percentag
patient
fatal
outcom
seem
develop
igm
field
studi
also
agreement
find
patient
evacu
europ
us
medic
treatment
recent
west
african
evd
outbreak
surviv
evd
patient
mount
earli
igm
respons
show
upregul
serum
igg
cours
diseas
correl
viral
clearanc
kreuel
et
al
wolf
et
al
convers
defici
diminish
igm
igg
respons
report
fatal
case
evd
mvd
van
paassen
et
al
baiz
et
al
howev
limit
field
data
also
indic
survivor
develop
igg
well
patient
die
develop
detect
circul
antiebov
antibodi
onyango
et
al
addit
limit
clinic
data
obtain
sudvcaus
evd
outbreak
gulu
uganda
reveal
signific
differ
humor
respons
fatal
nonfat
evd
late
express
igg
group
unrel
viral
clearanc
mani
aspect
evd
immunolog
kinet
antibodi
respons
statist
relev
cohort
acutestag
patient
defin
outcom
must
studi
antibodi
play
mani
role
immun
respons
pathogen
includ
neutral
antibodydepend
kill
virusinfect
cell
target
fc
receptor
bear
cell
adcc
complement
cmc
neutral
antibodi
n
ab
probabl
play
small
role
recoveri
acut
evd
sinc
mani
survivor
n
ab
detect
week
even
month
recoveri
luczkowiak
et
al
sobarzo
et
al
puzzl
yet
unexplain
find
one
plausibl
hypothes
disrupt
lymphoid
architectur
acut
evd
infect
may
compromis
germin
center
format
b
cell
affin
matur
featur
observ
lassa
fever
carrion
et
al
howev
hypothesi
reconcil
easili
level
circul
plasmablast
patient
acut
stage
ill
mcelroy
et
al
limit
focal
necrosi
observ
human
biopsi
sampl
lymphoid
tissu
martin
et
al
one
interest
possibl
long
filament
shape
filoviru
virion
may
requir
highli
divers
repertoir
n
ab
effect
neutral
fact
studi
found
greater
b
cell
clonal
evd
survivor
individu
b
cell
memori
influenza
viru
bornholdt
et
al
still
whole
stori
similar
delay
n
ab
product
describ
viral
hemorrhag
fever
eg
lassa
fever
perhap
importantli
delay
n
ab
product
strongli
suggest
longterm
viru
antigen
persist
agreement
durat
postevd
sequela
see
nevertheless
longterm
survivor
develop
effect
n
ab
mainli
direct
sever
epitop
ebolavir
gp
bornholdt
et
al
b
misasi
et
al
corti
et
al
mani
describ
n
ab
isol
survivor
direct
gp
glycan
cap
well
region
bridg
seem
epitop
amen
antibodybas
therapeut
like
zmapp
murin
et
al
importantli
number
studi
surviv
patient
highlight
presenc
natur
occur
n
ab
crossreact
ebolavirus
even
marv
olal
et
al
misasi
et
al
bornholdt
et
al
find
strongli
suggest
antibodymedi
immun
memori
may
provid
longterm
protect
secondari
infect
filovirus
may
import
implic
public
health
measur
eg
recruit
survivor
caregiv
futur
outbreak
current
rel
import
n
ab
versu
antibodymedi
mechan
adcc
cmc
unclear
even
though
protect
antibodi
probabl
act
neutral
adcccmc
activ
schmaljohn
lewi
antibodi
neutral
adcc
capac
detect
evd
survivor
decad
recoveri
adcc
probabl
import
mechanist
featur
zmapp
oling
et
al
addit
dissect
whether
neutral
adcc
specif
contribut
evd
immun
import
determin
kinet
antibodymedi
immun
acut
infect
longterm
recoveri
lack
inform
evd
antibodi
kinet
ebovspecif
quantit
activ
probabl
larg
respons
lack
protect
effect
demonstr
convalesc
plasma
therapi
van
griensven
et
al
therapeut
strategi
put
applic
field
outbreak
condit
requir
character
viru
specif
activ
product
well
optim
ensur
transfer
suffici
quantiti
protect
antibodi
cell
particularli
cell
essenti
clearanc
acut
viral
infect
cell
react
stimul
pathogenspecif
peptid
massiv
expand
differenti
effector
cell
migrat
peripher
infect
site
elimin
infect
cell
see
zhang
bevan
review
cell
activ
dc
banchereau
steinman
initi
assumpt
ebovinduc
dc
inactiv
would
turn
result
poor
cell
prime
overal
inabl
host
elimin
infect
hypothesi
substanti
earli
studi
demonstr
despit
spare
infect
mani
cell
underw
apoptosi
human
evd
baiz
et
al
wauquier
et
al
observ
still
valid
data
gather
mainli
recent
west
african
outbreak
suggest
lymphocyt
gener
display
dynam
kinet
evd
may
includ
earli
prolifer
follow
lymphopenia
kreuel
et
al
wolf
et
al
similar
dynam
occur
system
viral
infect
proinflammatori
disord
sepsi
luan
et
al
suggest
perhap
lymphopenia
differenti
characterist
evd
substanti
differ
earlier
studi
carri
context
recent
outbreak
applic
multiparametr
flow
cytometri
allow
first
time
collect
phenotyp
function
inform
singl
cell
unpreced
detail
studi
reveal
fact
evd
character
massiv
cell
activ
rather
inhibit
surviv
fatal
case
coexpress
activ
marker
hladr
well
prolifer
marker
like
detect
signific
percentag
cell
evd
patient
mcelroy
et
al
ruibal
et
al
compar
magnitud
activ
observ
acut
infect
vaccin
lindgren
et
al
miller
et
al
note
sinc
coexpress
hladr
correl
engag
cell
receptor
appay
et
al
find
strongli
suggest
proper
cell
prime
antigenpres
cell
occur
evd
human
addit
find
compar
patient
receiv
experiment
therapi
mcelroy
et
al
receiv
support
care
field
indic
robust
cell
activ
characterist
evd
unrel
treatment
paramount
question
therefor
robust
cell
activ
lead
viral
clearanc
evd
extent
lack
cell
effect
may
relat
defect
neg
immun
checkpoint
name
molecular
mechan
control
transit
activ
immun
homeostasi
essenti
autoimmun
control
buchbind
desai
two
mechan
trigger
cell
coinhibitor
molecul
program
cell
cytotox
tlymphocyteassoci
protein
earlier
review
alreadi
hypothes
cell
dysfunct
filoviru
infect
could
relat
high
express
cell
mohamadzadeh
et
al
lead
nonfunct
revers
statu
term
cell
exhaust
wherri
studi
recent
west
african
evd
outbreak
found
peripher
blood
cell
evd
patient
express
high
level
mcelroy
et
al
ruibal
et
al
significantli
higher
fatal
case
followup
observ
studi
determin
correl
high
express
cell
inhibitori
molecul
cell
function
apoptosi
import
determin
correl
like
requir
relev
vivo
model
reproduc
cell
phenotyp
util
immunotherapeut
approach
block
function
postexposur
filoviru
infect
treatment
may
provid
interest
opportun
sever
therapeut
product
licens
extens
block
sever
type
cancer
therebi
restor
cell
function
see
sharma
allison
review
anoth
import
relat
question
whether
broad
polyfunct
cell
respons
lead
increas
diseas
manifest
like
hantaviru
cardio
pulmonari
syndrom
terajima
enni
decreas
suscept
dengu
viru
infect
weiskopf
et
al
answer
question
exhaust
analysi
ebov
cell
immunodomin
human
must
perform
still
avail
previou
evid
show
viral
nucleoprotein
np
drive
cell
respons
mcelroy
et
al
sundar
et
al
wilson
hart
find
consist
observ
hla
allel
recogn
conserv
filoviru
np
epitop
provid
protect
sudv
infect
sanchez
et
al
addit
studi
hla
associ
evd
outcom
statist
signific
cohort
patient
highli
need
strengthen
initi
observ
find
np
drive
cell
respons
also
signific
implic
vaccin
design
may
explain
least
extent
gp
base
vaccin
induc
poor
cell
immun
agnandji
et
al
ewer
et
al
zhu
et
al
degre
electrolyt
abnorm
contribut
evd
pathogenesi
appreci
earlier
outbreak
respons
realtim
serum
electrolyt
data
avail
abil
acquir
measur
patient
west
african
evd
outbreak
well
degre
profus
wateri
diarrhea
report
brought
forefront
sever
electrolyt
imbal
evd
impact
electrolyt
could
patient
outcom
data
first
collect
sudv
outbreak
gulu
uganda
elev
buncr
level
hypocalcemia
associ
sever
diseas
fatal
outcom
data
african
cohort
hunt
et
al
combin
data
repatri
patient
care
develop
nation
uyeki
et
al
reveal
potassium
abnorm
hyponatremia
hypomagnesemia
hypocalcemia
alter
may
relat
acut
renal
injuri
also
common
among
sever
ill
patient
other
might
relat
volum
electrolyt
imbal
secondari
profus
wateri
diarrhea
clinic
consequ
electrolyt
imbal
could
includ
cardiac
arrhythmia
seizur
coma
inde
repatri
patient
exhibit
arrhythmia
electrocardiograph
chang
one
patient
seizur
three
coma
uyeki
et
al
electrolyt
level
easili
measur
blood
chemistri
paramet
correct
electrolyt
fluid
administr
measur
may
contribut
improv
outcom
recent
outbreak
one
evd
treatment
center
incorpor
data
patient
manag
case
fatal
rate
significantli
lower
rate
report
two
treatment
center
sierra
leon
hunt
et
al
schieffelin
et
al
lanini
et
al
multipl
line
evid
suggest
endothelium
dysfunct
evd
endotheli
cell
directli
infect
show
signific
cytopath
effect
endotheli
infect
thought
occur
termin
phase
ill
martin
et
al
geisbert
et
al
overal
dysfunct
endothelium
thought
indirect
effect
proinflammatori
cytokin
like
tnfalpha
villing
et
al
feldmann
et
al
molecul
like
nitric
oxid
increas
permeabl
endothelium
inflamm
increas
level
sever
proinflammatori
cytokin
chemokin
associ
evdrel
death
baiz
et
al
wauquier
et
al
gupta
et
al
hutchinson
rollin
mcelroy
et
al
b
infect
antigenpres
cell
macrophag
dc
monocyt
presum
sourc
cytokin
feldmann
et
al
gupta
et
al
cytokin
lead
endotheli
activ
increas
vascular
permeabl
due
loosen
endotheli
barrier
normal
necessari
physiolog
function
allow
cell
biomolecul
reach
site
inflamm
widespread
activ
mani
inflammatori
diseas
result
fluid
movement
detriment
host
clinic
laboratori
find
evd
includ
tachypnea
without
pulmonari
edema
hypotens
oliguria
tachycardia
impair
distal
perfus
hypoalbuminemia
hemoconcentr
consist
fluid
extravas
extravascular
space
secondari
increas
vascular
permeabl
uyeki
et
al
hunt
et
al
chertow
et
al
constel
clinic
find
thought
ultim
lead
hypovolem
shock
fatal
case
recent
year
addit
evid
dysfunct
endothelia
contribut
diseas
process
includ
find
increas
level
sicam
thrombomodulin
pecam
pselectin
patient
sever
fatal
diseas
mcelroy
et
al
b
biomark
releas
plasma
indic
activ
endothelium
andor
breakdown
endotheli
intercellular
junction
activ
endothelium
proinflammatori
procoagul
like
contribut
ongo
inflammatori
respons
character
sever
evd
coagulopathi
observ
patient
discuss
detail
also
noteworthi
sometim
conflict
bodi
evid
implic
viral
glycoprotein
gp
endotheli
dysfunct
ebov
gp
gene
code
region
produc
two
protein
base
transcript
edit
site
solubl
gp
sgp
fulllength
structur
gp
sanchez
et
al
fulllength
gp
produc
pseudotyp
retroviru
virionlik
particl
vlp
bind
activ
endotheli
cell
lead
increas
endotheli
permeabl
wahljensen
et
al
yang
et
al
sgp
detect
plasma
infect
individu
fact
inhibit
tnfmediat
increas
vascular
permeabl
vitro
perhap
suggest
compensatori
mechan
control
virusinduc
inflamm
third
form
protein
known
shed
gp
shed
surfac
infect
cell
vitro
increas
permeabl
cultur
endotheli
cell
escuderoperez
et
al
shed
gp
detect
infect
guinea
pig
yet
detect
vivo
human
final
overexpress
gp
explant
human
porcin
nhp
blood
vessel
lead
increas
endotheli
permeabl
endotheli
cytotox
mediat
mucin
domain
protein
yang
et
al
relev
find
evd
unclear
sinc
endotheli
cell
infect
long
endotheli
function
alreadi
compromis
show
cytopath
effect
infect
vitro
geisbert
et
al
taken
togeth
data
suggest
variou
form
ebov
gp
may
modul
endotheli
function
precis
role
protein
human
evd
pathogenesi
unclear
monik
viral
hemorrhag
fever
appli
ebov
evd
first
outbreak
identifi
appropri
fatal
case
hemorrhag
manifest
mostli
melena
ebola
haemorrhag
fever
zair
zair
outbreak
uniqu
rout
viru
transmiss
via
inject
approxim
onethird
patient
mode
entri
could
contribut
manifest
sever
diseas
author
note
patient
infect
inject
die
notabl
concurr
outbreak
sudvcaus
evd
also
high
frequenc
hemorrhag
manifest
howev
sever
larger
subsequ
outbreak
appropri
data
avail
significantli
fewer
patient
hemorrhag
manifest
diseas
ebov
sudv
bdbv
okwar
et
al
macneil
et
al
bwaka
et
al
addit
three
outbreak
associ
observ
bleed
death
argu
commonli
held
belief
hemorrhag
equat
fatal
outcom
furthermor
western
african
outbreak
hemorrhag
manifest
rare
report
fewer
patient
liberia
sierra
leon
bleed
symptom
record
chertow
et
al
schieffelin
et
al
lado
et
al
yan
et
al
dallatomasina
et
al
li
et
al
qin
et
al
two
report
singl
center
guinea
report
bleed
patient
barri
et
al
bah
et
al
perhap
report
differ
hemorrhag
frequenc
relat
genet
nutrit
factor
control
observ
report
regardless
hemorrhag
occur
evd
promin
featur
contrast
hemorrhag
seem
common
patient
featur
mvd
base
upon
limit
data
two
largest
outbreak
date
colebund
et
al
roddi
et
al
hemorrhag
clinic
sign
secondari
multipl
type
hematolog
disord
simplest
term
two
gener
categori
hematolog
disord
manifest
clinic
bleed
low
level
platelet
coagul
factor
defici
hunt
platelet
count
routin
measur
patient
evd
one
studi
patient
evd
west
african
outbreak
platelet
count
especi
low
rang
l
normal
rang
hunt
et
al
interestingli
phenomenon
note
year
ago
nhp
model
absolut
platelet
count
low
platelet
function
sever
affect
result
vivo
activ
degranul
fisherhoch
et
al
measur
platelet
function
report
date
human
howev
elev
level
observ
surviv
patient
evd
caus
sudv
mcelroy
et
al
b
sinc
platelet
major
sourc
bloodstream
henn
et
al
find
suggest
platelet
activ
human
evd
data
suggest
process
consum
platelet
function
activ
sever
fatal
evd
process
would
consist
find
lethal
nhp
studi
evd
level
elev
initi
declin
undetect
time
death
ebihara
et
al
marv
might
bit
differ
sinc
origin
report
first
outbreak
europ
patient
sever
thrombocytopenia
sometim
less
l
martini
coincid
signific
hemorrhag
half
patient
final
type
bleed
often
describ
evd
mvd
patientsepistaxi
conjunctiv
hemorrhag
bleed
gi
tract
oral
cavityi
mostli
mucos
natur
consist
loss
platelet
number
function
second
gener
categori
hematolog
disord
manifest
bleed
defici
coagul
factor
coagul
factor
quantit
clinic
measur
partial
thromboplastin
time
ptt
prothrombin
time
pt
evalu
intrins
extrins
coagul
pathway
unfortun
measur
report
case
studi
provid
consensu
regard
level
pt
ptt
evd
clear
inform
gap
need
address
earli
report
marv
state
ptt
pt
measur
patient
valu
obtain
explain
observ
sever
hemorrhag
martini
dic
often
seen
critic
ill
patient
especi
sepsi
involv
low
platelet
count
coagul
factor
defici
bleed
seen
patient
evd
often
report
due
dic
although
whether
criteria
dic
met
unknown
necessari
laboratori
test
routin
avail
dic
laboratori
featur
includ
thrombocytopenia
elev
fibrin
split
product
prolong
pt
consumpt
fibrinogen
levi
et
al
note
level
thrombocytopenia
seen
evd
patient
rare
meet
criteria
assign
dic
score
elev
fibrin
split
product
ddimer
measur
retrospect
elev
evd
patient
associ
fatal
outcom
pt
measur
normal
avail
case
report
sueblinvong
et
al
fibrinogen
level
associ
outcom
hemorrhag
manifest
mcelroy
et
al
mcelroy
et
al
b
measur
dic
marker
clearli
area
requir
addit
studi
clarif
less
convent
evalu
factor
involv
coagul
pathway
also
conduct
thrombomodulin
protein
express
endotheli
cell
anticoagul
properti
microenviron
cell
surfac
present
plasma
thrombomodulin
act
global
shown
one
famili
genet
defici
result
elev
level
free
plasma
thrombomodulin
associ
bleed
disord
langdown
et
al
endotheli
cell
also
releas
thrombomodulin
becom
activ
elev
plasma
level
thrombomodulin
associ
hemorrhag
death
sudv
patient
sever
diseas
cohort
evd
patient
mcelroy
et
al
mcelroy
et
al
b
suggest
loss
protein
endotheli
surfac
exacerb
endotheli
dysfunct
coagulopathi
evd
addit
tissu
factor
implic
coagulopathi
observ
nhp
geisbert
et
al
also
elev
patient
sever
evd
von
willebrand
factor
vwf
protein
present
platelet
endotheli
cell
mediat
interact
platelet
damag
endothelium
elev
sudvinfect
patient
hemorrhag
pediatr
sudvinfect
patient
fatal
outcom
also
elev
ebovinfect
patient
sever
diseas
mcelroy
et
al
complex
interplay
activ
endotheli
cell
activ
platelet
inflamm
coagulopathi
clearli
work
evd
interven
one
aspect
network
impact
human
diseas
still
unknown
would
invalu
determin
effect
evd
outcom
readili
avail
clinic
product
affect
aspect
process
compound
interest
statin
stabil
endothelium
solubl
gpiba
inhibit
interact
platelet
vwf
appear
consum
sever
diseas
one
key
larg
unaddress
question
role
coinfect
comorbid
evd
pathogenesi
especi
relev
patient
popul
affect
african
nation
possibl
contribut
malnutrit
malari
coinfect
diseas
process
malnutrit
preval
region
affect
evd
wirth
et
al
longstand
malnutrit
lead
defect
innat
adapt
cellular
immun
respons
schaibl
kaufmann
malnutrit
may
contribut
high
case
fatal
rate
observ
evd
outbreak
africa
compar
filovir
infect
patient
repatri
us
europ
uyeki
et
al
martini
malaria
coinfect
like
increas
evdrel
mortal
although
rigor
evalu
studi
effect
variou
antimalari
drug
conduct
west
african
outbreak
antimalari
drug
routin
given
evdposit
patient
etc
foya
liberia
time
artesunatelumefantrin
shortag
artesunateamodiaquin
prescrib
amodiaquin
prepar
associ
improv
surviv
malarianeg
patient
interestingli
suggest
direct
antivir
effect
effect
lost
malariaposit
patient
suggest
malaria
evd
coinfect
lead
wors
outcom
even
malaria
treat
gignoux
et
al
also
potenti
consequ
coinfect
hiv
hepatotrop
virus
hiv
coinfect
examin
one
studi
sudv
outbreak
gulu
test
patient
antibodi
test
differ
evd
outcom
observ
base
upon
hiv
statu
studi
mcelroy
et
al
b
count
obtain
possibl
case
newli
acquir
patient
yet
immunecompromis
enough
infect
influenc
evd
outcom
one
studi
evalu
publicli
avail
nextgener
sequenc
data
use
cohort
patient
posit
coinfect
gb
viru
c
common
clinic
innocu
pegiviru
infect
result
improv
outcom
evd
infect
lauck
et
al
result
somewhat
confound
fact
age
major
determin
gb
viru
c
infect
outcom
evd
special
mention
must
made
earli
data
regard
effect
age
ebov
suscept
dowel
outcom
muper
et
al
mcelroy
et
al
b
repeatedli
observ
larg
cohort
west
african
outbreak
team
et
al
fay
et
al
li
et
al
schieffelin
et
al
bower
et
al
case
fatal
rate
high
children
lowest
schoolag
children
reach
nadir
around
puberti
increas
peak
elderli
phenomenon
seen
infecti
diseas
children
suggest
perhap
schoolag
children
perfect
immunolog
window
life
fulli
matur
function
immun
system
without
alter
occur
secondari
influenc
sex
hormon
date
one
studi
examin
pediatr
patient
laboratori
evid
protect
effect
evd
studi
demonstr
pediatr
patient
viral
load
similar
adult
patient
mcelroy
et
al
b
thu
appear
control
viremia
better
howev
higher
level
rant
cell
chemokin
associ
pediatr
surviv
associ
seen
adult
thu
stronger
immun
respons
pediatr
patient
might
contribut
better
outcom
remain
proven
definit
requir
addit
research
effort
perhap
one
strike
find
western
african
evd
outbreak
identif
sever
sequela
evd
survivor
long
recoveri
sequela
import
implic
medic
treatment
public
health
one
year
identif
ebov
zair
marv
success
isol
ocular
fluid
convalesc
patient
uveiti
gear
et
al
later
followup
studi
describ
arthralgia
myalgia
abdomin
pain
common
sequela
evd
survivor
kikwit
outbreak
similar
find
individu
long
recoveri
bdbv
infect
clark
et
al
suggest
postrecoveri
sequela
may
common
filoviru
infect
date
ebov
rna
detect
semen
ocular
fluid
cerebrospin
fluid
breast
milk
bodi
fluid
evd
survivor
sever
week
even
month
discharg
green
et
al
chughtai
et
al
moreov
infecti
viru
isol
semen
uyeki
et
al
ocular
fluid
varkey
et
al
saliva
breast
milk
epidemiolog
evid
sexual
ebov
transmiss
establish
mate
et
al
import
task
determin
pathogen
potenti
viru
isol
semen
compar
blood
patient
sexual
transmiss
seem
uncommon
base
larg
number
male
survivor
sexual
transmiss
event
viru
isol
semen
may
less
infecti
either
due
attenu
mutat
inactiv
ebovspecif
antibodi
secret
mucos
surfac
gener
pathogen
featur
evd
sequela
put
physiolog
mechan
poorli
understood
importantli
mani
symptom
report
evd
survivor
well
observ
sign
like
uveiti
skin
desquam
suggest
inflammatori
syndrom
inde
immun
activ
persist
acut
phase
evd
mcelroy
et
al
row
et
al
strongli
suggest
continu
immun
stimul
postinfect
autoimmun
hypothes
still
need
experiment
test
consist
viru
persist
immunoprivileg
site
altern
sustain
inflamm
could
due
deposit
immun
complex
joint
viral
antigen
persist
seen
commonli
alphaviru
infect
influenza
viru
infect
respect
hoarau
et
al
tamburini
et
al
tapp
et
al
sinc
evd
survivor
suffer
sequela
factor
lead
postevd
syndrom
must
determin
comorbid
coinfect
like
contribut
sequela
develop
particularli
involv
immun
phenomena
like
bystand
cell
activ
fujinami
et
al
also
posit
correl
describ
viremia
level
acut
phase
evd
increas
risk
sequela
mattia
et
al
find
suggest
infect
ebov
may
confin
immunoprivileg
site
treatment
host
immun
respons
lead
viral
persist
phenomenon
would
favor
high
viral
load
consist
hypothesi
one
surviv
patient
high
viru
load
viru
persist
even
within
central
nervou
system
follow
viru
reactiv
meningoenceph
futur
caus
molecular
mechan
postevd
syndrom
must
determin
particular
assess
whether
reactiv
infecti
viru
involv
sequela
develop
key
due
magnitud
west
african
outbreak
high
number
surviv
individu
import
issu
need
address
establish
adequ
medic
countermeasur
public
health
polici
